Skip to content

Evaluation of the Biop Colposcopy System's Safety and Performance (Accuracy of Its Registration Procedure)

Bio Colposcopy System CIP: Evaluation of the Biop Colposcopy System's Safety and Performance (Accuracy of Its Registration Procedure)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03750214
Enrollment
26
Registered
2018-11-21
Start date
2020-05-31
Completion date
2020-12-31
Last updated
2020-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer Screening

Brief summary

This is a multi-center, prospective, non-randomized, confirmatory study to evaluate the safety and performance of the Biop Digital Colposcope and the accuracy of the image registration procedure between the Biop Digital Colposcope unit and the Biop Micro Colposcope probe unit.

Detailed description

This is a multi-center, prospective, non-randomized, confirmatory study to evaluate the safety and performance of the Biop Digital Colposcope and the accuracy of the image registration procedure between the Biop Digital Colposcope unit and the Biop Micro Colposcope probe unit. The Biop Digital Colposcope is intended for magnified viewing of the tissues of the vagina, cervix and external genitalia in order to assist doctors in diagnosing abnormalities such as lesions or cancer, and selecting areas for biopsy. The images from the digital colposcope are to be viewed on a color display. The digital colposcope is intended for use in hospitals, clinics, and doctor's offices. The Biop Micro Colposcope probe unit is an imaging tool intended to be placed in the vagina for acquisition of images of the cervix. It is intended as an adjunct to the Biop Digital Colposcope. It should NOT be used as a substitute for a thorough colposcopic evaluation. The Biop Micro Colposcope Probe unit is not intended for use on the vulva and vagina. It is anticipated that it will take approximately 3 months to complete active enrollment. Study duration for each subject is 1-2 days, including screening, enrolment and procedure. The study will be completed when the final study subject has completed the procedure. 1. Performance - to confirm that average image registration error is less than or equal to (≤) 2mm. 2. Safety - to evaluate the safety of the Biop Digital Colposcope in women undergoing cervical colposcopy procedures.

Interventions

DEVICEBiop Colposcopy System

The procedure stages: 1. Scanning of the cervix - the cervix is scanned using the micro colposcope probe unit, to produce a total of 51 micro-images and one macro image from the panoramic camera. 2. Colposcopy exam - during the standard colposcopy exam, the doctor acquires a panoramic image of the cervix with the digital colposcope. 3. A questionnaire completed by the subject after the Biop procedure, with regards to any unusual sensations or events experienced during the procedure. 4. A questionnaire completed by the user after the Biop procedure, with regards to system usage 5. Image Registration analysis

Sponsors

BIOP Medical
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
22 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Females, ages 22 to 65 years old * Referred for colposcopy, following abnormal cervical cytology * Subject provides signed informed consent

Exclusion criteria

* Currently pregnant or nursing * Currently menstruating * Currently has intrauterine device (IUD) * Diagnosed with diseases that may influence the color of the tissue, e.g., hepatitis, polycytemia vera. * Diagnosed with pathologies that affect blood coagulation, the immune system or undergoing any treatment that interfere with coagulation or the immune system * HIV-positive status * Psychological instability, inappropriate attitude or motivation * Use of any additional experimental drug or device or participation in another clinical study within the past 30 days

Design outcomes

Primary

MeasureTime frameDescription
Performanceprocedure day ± 1 dayThe primary performance endpoint is the image registration success. Image registration success is defined by the registration error (distance between corresponding control points following registration). Average image registration error should be less than or equal to (≤) to 2mm.
frequency and incidence of all Adverse Eventsprocedure day ± 1 daySafety endpoints include frequency and incidence of all Adverse Events (AE) and Serious Adverse Events (SAE) related and unrelated to the device use.

Other

MeasureTime frameDescription
Exploratory Endpointprocedure day ± 1 daySubject's comfort - as measured by a questionnaire

Contacts

Primary ContactDana Raveh Arbel
dana@biopmedical.com972528591891

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026